Oncology Business Management | Specialty

End-of-Life Treatment Has Important Nuances

October 13th 2019

Even if a disease is diagnosed as “incurable,” or progression to a state of incurability subsequently develops, the time between diagnosis and death is being prolonged and the quality of life improved with novel oncologic interventions, such that continued therapeutic efforts are justified.

New ASCO System Confronts Lack of EHR Interoperability

October 3rd 2019

With the recent launch of a free, open-source system for standardizing the electronic storage of patient records, the American Society of Clinical Oncology hopes to improve information flow across electronic health record platforms and curtail the harms of information blocking by private aggregators and vendors of patient information.

CFS&reg Experts: Novel Therapies and Onco-Genomics Add Heft to Precision Medicine

October 2nd 2019

Co-chairs William K. Oh, MD, Adam M. Brufsky, MD, PhD, and Benjamin P. Levy, MD, preview key topics that will be covered at the 37th Annual CFS®: Innovative Cancer Therapy for Tomorrow symposium.

Informed Consent Means Patients Should Be Informed

October 1st 2019

There is no more important principle in the conduct of legitimate therapeutic investigation than ensuring the adequacy of informed consent of the prospective clinical trial participant.

Medical Partners Open Phase I Trial Center to Improve Access, Novel Drug Development

September 27th 2019

Atlantic Health System of Morristown New Jersey and Translational Genomics Research Institute of Arizona have opened a center dedicated to phase I clinical trials in cancer and improving access for patients with limited coverage.

Therapeutic Vaccines Lead the Charge in HPV-Driven Cancers

September 24th 2019

The development of therapeutic vaccines for patients with cancers associated with the human papillomavirus has emerged as a leading strategy in continuing research efforts to address the growing public health threat posed by the virus.

Small Subgroups May Hold Big Clinical Clues in Oncology

September 23rd 2019

With the revolution in our understanding of cancer’s basic molecular biology, it is increasingly evident that subgroups of cancer originating from specific regions of the body have unique natural histories and respond to very different therapeutics. For example, the importance of BRCA mutations, which define a subset of ovarian cancers impressively sensitive to PARP inhibitors, has striking altered the management of this group of gynecologic malignancies.

The FDA Could Help Address Financial Toxicity During the Approval Process

September 21st 2019

Given the widespread financial impact the high cost of cancer drugs has on the healthcare system, it may be time for the FDA to take a broader approach when reviewing oncology drug applications. By also examining the cost of the drug, the FDA could shine a light on escalating drug costs and play a leadership role in creating new programs and initiatives that help patients pay for promising new therapies.

Experts Share Key Aspects of Cancer Care That Warrant Additional Publicity

September 4th 2019

OncLive interviewed experts at the State of the Science Summits in August 2019 on aspects of care in their field that they wish were publicized more.

Paying It Forward in Oncology: A Journey From Patient to Investigator

September 2nd 2019

Kristin Anderson, PhD, shares her journey from patient to investigator.

Oncology Fellow Stresses Integrity in the Lab and Clinic

August 28th 2019

Research forms the backbone of medical knowledge, and research integrity is a crucial responsibility of any scientist.

Even Superheroes Can Burn Out in Oncology

August 24th 2019

Yara Abdou, MD, sheds light on the challenging path of becoming an oncologist.

Rising Healthcare Costs Leave People Behind

August 23rd 2019

The cost of antineoplastic therapy and essential supportive care medications have a substantial negative impact on patients with cancer and their families.

Building Foundations for Understanding Drug Mechanisms in Oncology

August 18th 2019

A 2018 Giants of Cancer Care award winner for Drug Development, Joseph R. Bertino, MD, was an early pioneer in developing the understanding of methotrexate and its administration in cancer. His work has served as a platform for much broader investigation into the optimal use of other cancer agents. Along the way, Bertino has mentored many leaders in oncology and hematology and earned international recognition.

NCI Designations Propel Innovation at Two Prestigious Cancer Institutions

August 17th 2019

Residents of Indiana now have a National Cancer Institute–designated Comprehensive Cancer Center in their state, and Floridians have another designated Cancer Center in theirs. Both institutions, the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis and the University of Miami Sylvester Comprehensive Cancer Center, are OncLive® Strategic Alliance Partners.

Key Takeaway 6: Role of Immunotherapy in R/R mHCC

August 15th 2019

Key Takeaway 5: High AFP is a Biomarker for Ramucirumab

August 15th 2019

Key Takeaway 4: Second-Line Regorafenib After TKI in HCC

August 15th 2019

Key Takeaway 3: Role of Frontline I/O Still Pending

August 15th 2019

Key Takeaway 2: Initial Systemic Therapy in HCC

August 15th 2019